Skip to main content
Feature Interview

Gastrointestinal Bleeding After Left Atrial Appendage Occlusion: When Is Risk Highest?

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates. 

EP LAB DIGEST. 2026;26(11).

Interview by Jodie Elrod

Gastrointestinal Bleeding After Left Atrial Appendage Occlusion: When Is Risk Highest?
Adeesh Parvathaneni, MD

In this interview, EP Lab Digest speaks with Adeesh Parvathaneni, MD, about his presentation, "Incident Versus Prevalent Gastrointestinal Hemorrhage After Left Atrial Appendage Occlusion (LAAO): A Real-World Analysis of 39,021 Patients,” at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Could you start with a brief introduction about yourself?

My name is Adeesh Parvathaneni, and I’m a second-year internal medicine resident at the Tulane School of Medicine. My interests lie broadly in cardiology, with a particular interest in electrophysiology, including LAA procedures and newer procedures for patients with atrial fibrillation. I’m still early in my training, so I’m keeping my interests broad and look forward to seeing how they develop.

Can you provide an overview of your TCT presentation comparing incident versus prevalent gastrointestinal hemorrhage after left atrial appendage occlusion in a real-world population of 39,021 patients? 

I think the question I was most interested in with this specific analysis was: When do bleeding events occur after a LAA procedure? There are several types of devices, with the WATCHMAN device (Boston Scientific) probably being the most common. We wanted to see whether patients experienced gastrointestinal bleeding or other bleeding events within the first week or later, and when these events were most prevalent.

I thought it was interesting that some of the research showed that bleeding occurred mostly within the first 7 days, probably when patients are receiving the most anticoagulant and antiplatelet therapy. Some patients are taking apixaban, aspirin, and clopidogrel. Bleeding is somewhat expected, but you might expect the risk to be consistent throughout the 45 days they are taking those medications. What you actually see, however, is that most bleeding events occur within the first 7 to 14 days.

What are the key findings and take-home messages for clinicians caring for patients with a history of—or risk for—gastrointestinal bleeding who are being considered for LAAO?

I think the evidence in this field is still mixed, but one thing to keep in mind is that this procedure carries some risk. Some primary care clinicians or others referring patients may expect anticoagulation to be discontinued immediately after the procedure. In fact, some patients initially receive more intensive anticoagulation and are at higher risk of bleeding.

I think the biggest consideration for cardiologists is close follow-up during the first 7 days and making sure patients know what to watch for during the first 14 days. Telling patients, “If you notice any signs of melena or blood in your stool, go to the emergency department immediately,” can be very helpful.

The transcripts were edited for clarity and length.

Disclosures: Dr Parvathaneni has completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest, and has no conflicts of interest to report.